In October 2025, MingCeler Biotech obtained full AAALAC accreditation, laying a solid foundation for its expansion into overseas markets. AAALAC (Assessment and Accreditation of Laboratory Animal Care) International accreditation is one of the most authoritative certifications in the global field of animal experimentation. Achieving this accreditation signifies that MingCeler Biotech has reached internationally advanced standards in animal care management and animal welfare assurance. This not only affirms the company’s existing management system but also establishes a robust groundwork for its future entry into the international market.
 

 

The attainment of AAALAC accreditation is both an honor and a responsibility and motivation for MingCeler Biotech. Moving forward, the company will continue to increase investment in research and development, enhance its independent innovation capabilities, and deliver higher-quality products and services to its customers. With an unwavering commitment to technological innovation and strict quality management, MingCeler Biotech is dedicated to providing stronger support for global life sciences and health research as a specialized, sophisticated, and innovative enterprise.

 

MingCeler is committed to the development and application of the most advanced next-generation animal model technology, TurboMice™ technology, which was developed by Dr. Wu Guangming through a series of optimizations of tetraploid complementation technology and precise editing of stem cells. It can achieve editing of almost any target gene locus in 3-5 months. MingCeler is the world's first company to realize the transformation of Tetraploid Complementation technology from the laboratory to industrial applications. TurboMice™ technology has overcome the technical challenges of long modeling periods and low success rates of complex model mice. Through the industrialization of TurboMice™ technology, we can provide high-end model mice products and services for global universities, research institutes, hospitals, and pharmaceutical companies involved in life health research.